ID   AICDA_HUMAN             Reviewed;         198 AA.
AC   Q9GZX7; Q6QJ81; Q8NFC1;
DT   10-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   15-MAR-2017, entry version 146.
DE   RecName: Full=Single-stranded DNA cytosine deaminase;
DE            EC=3.5.4.38 {ECO:0000269|PubMed:18722174};
DE   AltName: Full=Activation-induced cytidine deaminase;
DE            Short=AID;
DE   AltName: Full=Cytidine aminohydrolase;
GN   Name=AICDA; Synonyms=AID;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=10950930; DOI=10.1006/geno.2000.6268;
RA   Muto T., Muramatsu M., Taniwaki M., Kinoshita K., Honjo T.;
RT   "Isolation, tissue distribution, and chromosomal localization of the
RT   human activation-induced cytidine deaminase (hAID) gene.";
RL   Genomics 68:85-88(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANTS
RP   HIGM2 TRP-24; ARG-80; PRO-106; VAL-139 AND SER-151.
RX   PubMed=11007475; DOI=10.1016/S0092-8674(00)00079-9;
RA   Revy P., Muto T., Levy Y., Geissmann F., Plebani A., Sanal O.,
RA   Catalan N., Forveille M., Dufourcq-Lagelouse R., Gennery A.,
RA   Tezcan I., Ersoy F., Kayserili H., Ugazio A.G., Brousse N.,
RA   Muramatsu M., Notarangelo L.D., Kinoshita K., Honjo T., Fischer A.,
RA   Durandy A.;
RT   "Activation-induced cytidine deaminase (AID) deficiency causes the
RT   autosomal recessive form of the Hyper-IgM syndrome (HIGM2).";
RL   Cell 102:565-575(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=12202747; DOI=10.1073/pnas.192442899;
RA   Martin A., Scharff M.D.;
RT   "Somatic hypermutation of the AID transgene in B and non-B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12304-12308(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Roa S., Gonzalez-Sarmiento R.;
RT   "Intracellular localization of AID isoforms.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14769937; DOI=10.1073/pnas.0307335101;
RA   Ito S., Nagaoka H., Shinkura R., Begum N., Muramatsu M., Nakata M.,
RA   Honjo T.;
RT   "Activation-induced cytidine deaminase shuttles between nucleus and
RT   cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide
RT   1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:1975-1980(2004).
RN   [9]
RP   PHOSPHORYLATION AT THR-27 AND SER-38, INTERACTION WITH PRKACA AND
RP   PRKAR1A, AND MUTAGENESIS OF THR-27 AND SER-38.
RX   PubMed=16387847; DOI=10.1073/pnas.0509969103;
RA   Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R.;
RT   "PKA-mediated phosphorylation regulates the function of activation-
RT   induced deaminase (AID) in B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:395-400(2006).
RN   [10]
RP   INTERACTION WITH CTNNBL1, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION AT SER-38, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF 39-ALA--PHE-42 AND SER-38.
RX   PubMed=18722174; DOI=10.1016/j.molcel.2008.07.009;
RA   Conticello S.G., Ganesh K., Xue K., Lu M., Rada C., Neuberger M.S.;
RT   "Interaction between antibody-diversification enzyme AID and
RT   spliceosome-associated factor CTNNBL1.";
RL   Mol. Cell 31:474-484(2008).
RN   [11]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [12]
RP   INTERACTION WITH CTNNBL1, FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS
RP   OF LYS-10; VAL-18; ARG-19; TRP-20; ARG-50; ARG-112 AND PHE-193, AND
RP   CHARACTERIZATION OF VARIANT TRP-24.
RX   PubMed=21385873; DOI=10.1074/jbc.M110.208769;
RA   Ganesh K., Adam S., Taylor B., Simpson P., Rada C., Neuberger M.;
RT   "CTNNBL1 is a novel nuclear localization sequence-binding protein that
RT   recognizes RNA-splicing factors CDC5L and Prp31.";
RL   J. Biol. Chem. 286:17091-17102(2011).
RN   [13]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-27.
RX   PubMed=21659520; DOI=10.1074/jbc.M111.235721;
RA   Demorest Z.L., Li M., Harris R.S.;
RT   "Phosphorylation directly regulates the intrinsic DNA cytidine
RT   deaminase activity of activation-induced deaminase and APOBEC3G
RT   protein.";
RL   J. Biol. Chem. 286:26568-26575(2011).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH SUPT6H.
RX   PubMed=21518874; DOI=10.1073/pnas.1104423108;
RA   Okazaki I.M., Okawa K., Kobayashi M., Yoshikawa K., Kawamoto S.,
RA   Nagaoka H., Shinkura R., Kitawaki Y., Taniguchi H., Natsume T.,
RA   Iemura S., Honjo T.;
RT   "Histone chaperone Spt6 is required for class switch recombination but
RT   not somatic hypermutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:7920-7925(2011).
RN   [15]
RP   INDUCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=23166356; DOI=10.1084/jem.20121387;
RA   Basso K., Schneider C., Shen Q., Holmes A.B., Setty M., Leslie C.,
RA   Dalla-Favera R.;
RT   "BCL6 positively regulates AID and germinal center gene expression via
RT   repression of miR-155.";
RL   J. Exp. Med. 209:2455-2465(2012).
RN   [16]
RP   INTERACTION WITH RNF126, AND UBIQUITINATION BY RNF126.
RX   PubMed=23277564; DOI=10.1073/pnas.1214538110;
RA   Delker R.K., Zhou Y., Strikoudis A., Stebbins C.E., Papavasiliou F.N.;
RT   "Solubility-based genetic screen identifies RING finger protein 126 as
RT   an E3 ligase for activation-induced cytidine deaminase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1029-1034(2013).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) OF 23-183 IN COMPLEX WITH ZINC.
RX   PubMed=27258794; DOI=10.1016/j.dnarep.2016.05.029;
RA   Pham P., Afif S.A., Shimoda M., Maeda K., Sakaguchi N., Pedersen L.C.,
RA   Goodman M.F.;
RT   "Structural analysis of the activation-induced deoxycytidine deaminase
RT   required in immunoglobulin diversification.";
RL   DNA Repair 43:48-56(2016).
RN   [18]
RP   VARIANT CYS-25.
RX   PubMed=11544457; DOI=10.1067/mai.2001.117456;
RA   Noguchi E., Shibasaki M., Inudou M., Kamioka M., Yokouchi Y.,
RA   Yamakawa-Kobayashi K., Hamaguchi H., Matsui A., Arinami T.;
RT   "Association between a new polymorphism in the activation-induced
RT   cytidine deaminase gene and atopic asthma and the regulation of total
RT   serum IgE levels.";
RL   J. Allergy Clin. Immunol. 108:382-386(2001).
RN   [19]
RP   VARIANTS HIGM2 TRP-24; TYR-56; ARG-80; ARG-87; PRO-106; VAL-139;
RP   SER-151 AND SER-174.
RX   PubMed=14962793; DOI=10.1016/j.clim.2003.10.007;
RA   Quartier P., Bustamante J., Sanal O., Plebani A., Debre M.,
RA   Deville A., Litzman J., Levy J., Fermand J.P., Lane P., Horneff G.,
RA   Aksu G., Yalcin I., Davies G., Tezcan I., Ersoy F., Catalan N.,
RA   Imai K., Fischer A., Durandy A.;
RT   "Clinical, immunologic and genetic analysis of 29 patients with
RT   autosomal recessive hyper-IgM syndrome due to activation-induced
RT   cytidine deaminase deficiency.";
RL   Clin. Immunol. 110:22-29(2004).
RN   [20]
RP   VARIANT HIGM2 LEU-15.
RX   PubMed=23803409; DOI=10.1016/j.clim.2013.05.017;
RA   Caratao N., Cortesao C.S., Reis P.H., Freitas R.F., Jacob C.M.,
RA   Pastorino A.C., Carneiro-Sampaio M., Barreto V.M.;
RT   "A novel activation-induced cytidine deaminase (AID) mutation in
RT   Brazilian patients with hyper-IgM type 2 syndrome.";
RL   Clin. Immunol. 148:279-286(2013).
RN   [21]
RP   VARIANTS HIGM2 HIS-31 AND PRO-130.
RX   PubMed=26545377; DOI=10.1007/s00251-015-0878-6;
RA   Ouadani H., Ben-Mustapha I., Ben-ali M., Ben-khemis L., Largueche B.,
RA   Boussoffara R., Maalej S., Fetni I., Hassayoun S., Mahfoudh A.,
RA   Mellouli F., Yalaoui S., Masmoudi H., Bejaoui M., Barbouche M.R.;
RT   "Novel and recurrent AID mutations underlie prevalent autosomal
RT   recessive form of HIGM in consanguineous patients.";
RL   Immunogenetics 68:19-28(2016).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS HIGM2 TYR-56 AND PRO-130, AND FUNCTION.
RX   PubMed=27716525; DOI=10.1016/j.molimm.2016.09.025;
RA   Ouadani H., Ben-Mustapha I., Ben-Ali M., Largueche B., Jovanic T.,
RA   Garcia S., Arcangioli B., Elloumi-Zghal H., Fathallah D., Hachicha M.,
RA   Masmoudi H., Rougeon F., Barbouche M.R.;
RT   "Activation induced cytidine deaminase mutant (AID-His130Pro) from
RT   Hyper IgM 2 patient retained mutagenic activity on SHM artificial
RT   substrate.";
RL   Mol. Immunol. 79:77-82(2016).
CC   -!- FUNCTION: Single-stranded DNA-specific cytidine deaminase.
CC       Involved in somatic hypermutation (SHM), gene conversion, and
CC       class-switch recombination (CSR) in B-lymphocytes by deaminating C
CC       to U during transcription of Ig-variable (V) and Ig-switch (S)
CC       region DNA. Required for several crucial steps of B-cell terminal
CC       differentiation necessary for efficient antibody responses
CC       (PubMed:18722174, PubMed:21385873, PubMed:21518874,
CC       PubMed:27716525). May also play a role in the epigenetic
CC       regulation of gene expression by participating in DNA
CC       demethylation (PubMed:21496894). {ECO:0000269|PubMed:18722174,
CC       ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:21496894,
CC       ECO:0000269|PubMed:21518874, ECO:0000269|PubMed:27716525}.
CC   -!- CATALYTIC ACTIVITY: Cytosine in single-stranded DNA + H(2)O =
CC       uracil in single-stranded DNA + NH(3).
CC       {ECO:0000269|PubMed:18722174}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:27258794};
CC   -!- SUBUNIT: Interacts with CTNNBL1; the interaction is important for
CC       the immunoglobulin switch activity of AICDA. Interacts (via its
CC       NLS) with KPNA1. Interacts with PKA/PRKACA and PRKAR1A/PKR1.
CC       Interacts with TRIM28 and NCL (By similarity). Interacts with
CC       SUPT6H. Interacts with RNF126. {ECO:0000250,
CC       ECO:0000269|PubMed:16387847, ECO:0000269|PubMed:18722174,
CC       ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:21518874,
CC       ECO:0000269|PubMed:23277564}.
CC   -!- INTERACTION:
CC       Q784Z8:C (xeno); NbExp=2; IntAct=EBI-3834328, EBI-11666471;
CC       P31689:DNAJA1; NbExp=6; IntAct=EBI-3834328, EBI-347834;
CC       O60884:DNAJA2; NbExp=3; IntAct=EBI-3834328, EBI-352957;
CC       P24522:GADD45A; NbExp=5; IntAct=EBI-3834328, EBI-448167;
CC       P11142:HSPA8; NbExp=2; IntAct=EBI-3834328, EBI-351896;
CC       Q13569:TDG; NbExp=5; IntAct=EBI-3834328, EBI-348333;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21385873}.
CC       Cytoplasm {ECO:0000269|PubMed:18722174,
CC       ECO:0000269|PubMed:21385873, ECO:0000269|PubMed:23166356}.
CC       Note=Predominantly cytoplasmic but shuttles between the nucleus
CC       and the cytoplasm. {ECO:0000269|PubMed:21385873}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9GZX7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9GZX7-2; Sequence=VSP_047803;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in lymph nodes and tonsils.
CC       {ECO:0000269|PubMed:23166356}.
CC   -!- INDUCTION: Negatively regulated by microRNA-155 (miR-155).
CC       {ECO:0000269|PubMed:23166356}.
CC   -!- PTM: Ser-38 is the major site whereas Thr-27 is the minor site of
CC       phosphorylation. Phosphorylation regulates its class-switch
CC       recombination activity. {ECO:0000269|PubMed:16387847,
CC       ECO:0000269|PubMed:18722174}.
CC   -!- PTM: Probably monoubiquitinated on several residues by RNF126.
CC       {ECO:0000269|PubMed:23277564}.
CC   -!- DISEASE: Immunodeficiency with hyper-IgM 2 (HIGM2) [MIM:605258]: A
CC       rare immunodeficiency syndrome characterized by normal or elevated
CC       serum IgM levels with absence of IgG, IgA, and IgE. It results in
CC       a profound susceptibility to bacterial infections.
CC       {ECO:0000269|PubMed:11007475, ECO:0000269|PubMed:14962793,
CC       ECO:0000269|PubMed:23803409, ECO:0000269|PubMed:26545377,
CC       ECO:0000269|PubMed:27716525}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytidine and deoxycytidylate deaminase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=AICDAbase; Note=AICDA mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/AICDAbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB040431; BAB12721.1; -; mRNA.
DR   EMBL; AB040430; BAB12720.1; -; Genomic_DNA.
DR   EMBL; AF529819; AAM95406.1; -; mRNA.
DR   EMBL; AY536516; AAS92920.1; -; mRNA.
DR   EMBL; BT007402; AAP36066.1; -; mRNA.
DR   EMBL; AC092184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006296; AAH06296.1; -; mRNA.
DR   CCDS; CCDS41747.1; -. [Q9GZX7-1]
DR   CCDS; CCDS81662.1; -. [Q9GZX7-2]
DR   RefSeq; NP_001317272.1; NM_001330343.1. [Q9GZX7-2]
DR   RefSeq; NP_065712.1; NM_020661.3. [Q9GZX7-1]
DR   UniGene; Hs.149342; -.
DR   PDB; 5JJ4; X-ray; 2.81 A; A/B/C=23-183.
DR   PDBsum; 5JJ4; -.
DR   ProteinModelPortal; Q9GZX7; -.
DR   SMR; Q9GZX7; -.
DR   BioGrid; 121497; 54.
DR   DIP; DIP-48519N; -.
DR   IntAct; Q9GZX7; 24.
DR   MINT; MINT-4717382; -.
DR   STRING; 9606.ENSP00000229335; -.
DR   iPTMnet; Q9GZX7; -.
DR   PhosphoSitePlus; Q9GZX7; -.
DR   BioMuta; AICDA; -.
DR   DMDM; 23813666; -.
DR   MaxQB; Q9GZX7; -.
DR   PaxDb; Q9GZX7; -.
DR   PeptideAtlas; Q9GZX7; -.
DR   PRIDE; Q9GZX7; -.
DR   DNASU; 57379; -.
DR   Ensembl; ENST00000229335; ENSP00000229335; ENSG00000111732. [Q9GZX7-1]
DR   Ensembl; ENST00000537228; ENSP00000445691; ENSG00000111732. [Q9GZX7-2]
DR   GeneID; 57379; -.
DR   KEGG; hsa:57379; -.
DR   UCSC; uc001qur.3; human. [Q9GZX7-1]
DR   CTD; 57379; -.
DR   DisGeNET; 57379; -.
DR   GeneCards; AICDA; -.
DR   HGNC; HGNC:13203; AICDA.
DR   MalaCards; AICDA; -.
DR   MIM; 605257; gene.
DR   MIM; 605258; phenotype.
DR   neXtProt; NX_Q9GZX7; -.
DR   OpenTargets; ENSG00000111732; -.
DR   Orphanet; 101089; Hyper-IgM syndrome type 2.
DR   PharmGKB; PA24644; -.
DR   eggNOG; ENOG410IFHW; Eukaryota.
DR   eggNOG; ENOG4111HYQ; LUCA.
DR   GeneTree; ENSGT00530000062933; -.
DR   HOGENOM; HOG000033754; -.
DR   HOVERGEN; HBG050434; -.
DR   InParanoid; Q9GZX7; -.
DR   KO; K10989; -.
DR   OMA; RNKNGCH; -.
DR   OrthoDB; EOG091G0J2L; -.
DR   PhylomeDB; Q9GZX7; -.
DR   TreeFam; TF331356; -.
DR   BRENDA; 3.5.4.38; 2681.
DR   SIGNOR; Q9GZX7; -.
DR   GeneWiki; AICDA; -.
DR   GenomeRNAi; 57379; -.
DR   PRO; PR:Q9GZX7; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111732; -.
DR   CleanEx; HS_AICDA; -.
DR   ExpressionAtlas; Q9GZX7; baseline and differential.
DR   Genevisible; Q9GZX7; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004126; F:cytidine deaminase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0080111; P:DNA demethylation; IDA:UniProtKB.
DR   GO; GO:0045190; P:isotype switching; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0090310; P:negative regulation of methylation-dependent chromatin silencing; IDA:UniProtKB.
DR   GO; GO:0016445; P:somatic diversification of immunoglobulins; IDA:UniProtKB.
DR   GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IMP:UniProtKB.
DR   InterPro; IPR016192; APOBEC/CMP_deaminase_Zn-bd.
DR   InterPro; IPR013158; APOBEC_N.
DR   InterPro; IPR002125; CMP_dCMP_Zn-bd.
DR   InterPro; IPR016193; Cytidine_deaminase-like.
DR   Pfam; PF08210; APOBEC_N; 1.
DR   SUPFAM; SSF53927; SSF53927; 1.
DR   PROSITE; PS00903; CYT_DCMP_DEAMINASES_1; 1.
DR   PROSITE; PS51747; CYT_DCMP_DEAMINASES_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; Hydrolase; Metal-binding; mRNA processing; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Ubl conjugation;
KW   Zinc.
FT   CHAIN         1    198       Single-stranded DNA cytosine deaminase.
FT                                /FTId=PRO_0000171687.
FT   DOMAIN       23    129       CMP/dCMP-type deaminase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01083}.
FT   REGION        2     26       Interaction with SUPT6H.
FT                                {ECO:0000269|PubMed:21518874}.
FT   REGION       39     42       Important for interaction with CTNNBL1.
FT                                {ECO:0000269|PubMed:18722174}.
FT   REGION       88    116       Required for interaction with RNF126.
FT                                {ECO:0000269|PubMed:23277564}.
FT   MOTIF         1     30       Bipartite nuclear localization signal.
FT                                {ECO:0000269|PubMed:14769937}.
FT   MOTIF       183    198       Nuclear export signal.
FT                                {ECO:0000269|PubMed:14769937}.
FT   ACT_SITE     58     58       Proton donor.
FT                                {ECO:0000250|UniProtKB:P0ABF6}.
FT   METAL        56     56       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:27258794}.
FT   METAL        87     87       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:27258794}.
FT   METAL        90     90       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:27258794}.
FT   MOD_RES      27     27       Phosphothreonine; by PKA.
FT                                {ECO:0000269|PubMed:16387847}.
FT   MOD_RES      38     38       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:16387847,
FT                                ECO:0000269|PubMed:18722174}.
FT   VAR_SEQ     143    152       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_047803.
FT   VARIANT      15     15       F -> L (in HIGM2).
FT                                {ECO:0000269|PubMed:23803409}.
FT                                /FTId=VAR_077563.
FT   VARIANT      24     24       R -> W (in HIGM2; completely abolishes
FT                                nuclear import and interaction with
FT                                CTNNBL1, diminishes interaction with
FT                                KPNA1 and abolishes immunoglobulin class
FT                                switching; dbSNP:rs104894324).
FT                                {ECO:0000269|PubMed:11007475,
FT                                ECO:0000269|PubMed:14962793,
FT                                ECO:0000269|PubMed:21385873}.
FT                                /FTId=VAR_013774.
FT   VARIANT      25     25       R -> C. {ECO:0000269|PubMed:11544457}.
FT                                /FTId=VAR_014091.
FT   VARIANT      31     31       Y -> H (in HIGM2).
FT                                {ECO:0000269|PubMed:26545377}.
FT                                /FTId=VAR_077564.
FT   VARIANT      56     56       H -> Y (in HIGM2; unknown pathological
FT                                significance; loss of mutagenic
FT                                activity). {ECO:0000269|PubMed:14962793,
FT                                ECO:0000269|PubMed:27716525}.
FT                                /FTId=VAR_077565.
FT   VARIANT      80     80       W -> R (in HIGM2; dbSNP:rs104894320).
FT                                {ECO:0000269|PubMed:11007475,
FT                                ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_013775.
FT   VARIANT      87     87       C -> R (in HIGM2; unknown pathological
FT                                significance; dbSNP:rs762590894).
FT                                {ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_077566.
FT   VARIANT     106    106       L -> P (in HIGM2; dbSNP:rs104894321).
FT                                {ECO:0000269|PubMed:11007475,
FT                                ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_013776.
FT   VARIANT     130    130       H -> P (in HIGM2; slightly decreased
FT                                mutagenic activity).
FT                                {ECO:0000269|PubMed:26545377,
FT                                ECO:0000269|PubMed:27716525}.
FT                                /FTId=VAR_077567.
FT   VARIANT     139    139       M -> V (in HIGM2; dbSNP:rs104894322).
FT                                {ECO:0000269|PubMed:11007475,
FT                                ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_013777.
FT   VARIANT     151    151       F -> S (in HIGM2; dbSNP:rs104894327).
FT                                {ECO:0000269|PubMed:11007475,
FT                                ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_013778.
FT   VARIANT     174    174       R -> S (in HIGM2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:14962793}.
FT                                /FTId=VAR_077568.
FT   MUTAGEN      10     10       K->A: Little effect on nuclear import;
FT                                when associated with A-193. No effect on
FT                                CTNNBL1 binding.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN      18     18       V->S: Greatly impaired nuclear import;
FT                                when associated with V-19 and A-193.
FT                                Reduced interaction with both CTNNBL1 and
FT                                KPNA1, and abolishes immunoglobulin class
FT                                switching; when associated with V-19.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN      19     19       R->V: Greatly impaired nuclear import;
FT                                when associated with S-18 and A-193.
FT                                Reduced interaction with both CTNNBL1 and
FT                                KPNA1, and abolishes immunoglobulin class
FT                                switching; when associated with S-18.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN      20     20       W->K: Impaired nuclear import; when
FT                                associated with A-193. No effect on
FT                                CTNNBL1 binding.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN      27     27       T->A: Loss of phosphorylation. No effect
FT                                on cytidine deaminase activity. Impaired
FT                                class-switch recombination activity.
FT                                {ECO:0000269|PubMed:16387847,
FT                                ECO:0000269|PubMed:21659520}.
FT   MUTAGEN      27     27       T->E: Phosphomimetic mutant which shows
FT                                loss of cytidine deaminase activity and
FT                                impaired class-switch recombination
FT                                activity. {ECO:0000269|PubMed:16387847,
FT                                ECO:0000269|PubMed:21659520}.
FT   MUTAGEN      38     38       S->A: Loss of phosphorylation. Impaired
FT                                class-switch recombination activity. No
FT                                effect on interaction with CTNNBL1.
FT                                {ECO:0000269|PubMed:16387847,
FT                                ECO:0000269|PubMed:18722174}.
FT   MUTAGEN      38     38       S->D: No effect on interaction with
FT                                CTNNBL1. {ECO:0000269|PubMed:16387847,
FT                                ECO:0000269|PubMed:18722174}.
FT   MUTAGEN      39     42       ATSF->GGQV: Greatly reduced interaction
FT                                with CTNNBL1 but no effect on subcellular
FT                                location, enzyme activity, ability to
FT                                oligomerize nor on phosphorylation at
FT                                Ser-38. Diminished antibody
FT                                diversification.
FT                                {ECO:0000269|PubMed:18722174}.
FT   MUTAGEN      50     50       R->G: Some reduced nuclear import; when
FT                                associated with A-193.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN     112    112       R->D: Greatly reduced nuclear import;
FT                                when associated with A-193.
FT                                {ECO:0000269|PubMed:21385873}.
FT   MUTAGEN     193    193       F->A: Completely abolishes nuclear
FT                                import; when associated with W-24 or D-
FT                                112. Little affect on nuclear import;
FT                                when associated with A-10. Greatly
FT                                impaired nuclear import; when associated
FT                                with K-20 or G-50. Almost completely
FT                                abolishes nuclear import; when associated
FT                                with S-18 and V-19.
FT                                {ECO:0000269|PubMed:21385873}.
FT   CONFLICT    119    119       R -> H (in Ref. 3; AAM95406).
FT                                {ECO:0000305}.
FT   STRAND       28     36       {ECO:0000244|PDB:5JJ4}.
FT   STRAND       42     50       {ECO:0000244|PDB:5JJ4}.
FT   HELIX        57     68       {ECO:0000244|PDB:5JJ4}.
FT   STRAND       74     84       {ECO:0000244|PDB:5JJ4}.
FT   HELIX        88     99       {ECO:0000244|PDB:5JJ4}.
FT   STRAND      104    112       {ECO:0000244|PDB:5JJ4}.
FT   HELIX       122    131       {ECO:0000244|PDB:5JJ4}.
FT   STRAND      135    138       {ECO:0000244|PDB:5JJ4}.
FT   HELIX       141    150       {ECO:0000244|PDB:5JJ4}.
FT   HELIX       165    179       {ECO:0000244|PDB:5JJ4}.
SQ   SEQUENCE   198 AA;  23954 MW;  3C27BB143DB184A9 CRC64;
     MDSLLMNRRK FLYQFKNVRW AKGRRETYLC YVVKRRDSAT SFSLDFGYLR NKNGCHVELL
     FLRYISDWDL DPGRCYRVTW FTSWSPCYDC ARHVADFLRG NPNLSLRIFT ARLYFCEDRK
     AEPEGLRRLH RAGVQIAIMT FKDYFYCWNT FVENHERTFK AWEGLHENSV RLSRQLRRIL
     LPLYEVDDLR DAFRTLGL
//
